依库珠单抗用于早发型子痫前期后延长妊娠一例
一例26岁初产妇孕20周出现新发微血管病性溶血性贫血,背景为控制不佳的1型糖尿病,因疑似非典型溶血性尿毒症综合征接受依库珠单抗治疗。孕24周发生重叠的早发型子痫前期,继续使用依库珠单抗后于孕27周分娩。结论认为依库珠单抗可能延长早发型子痫前期的妊娠,需进一步研究评估母婴短期和长期结局。
要点
- 孕20周新发微血管病性溶血性贫血,背景为控制不佳的1型糖尿病。
- 因疑似非典型溶血性尿毒症综合征接受依库珠单抗治疗。
- 孕24周发生重叠早发型子痫前期,继续用药后孕27周分娩。
核心结论
- 依库珠单抗可能延长早发型子痫前期的妊娠。
- 需要更多研究评估母婴短期和长期结局。
研究设计与样本
- 个案报道,1例26岁初产妇。
主要发现
- 孕20周出现新发微血管病性溶血性贫血,背景为控制不佳的1型糖尿病。
- 因疑似非典型溶血性尿毒症综合征接受依库珠单抗治疗。
- 孕24周发生重叠的早发型子痫前期,继续使用依库珠单抗后于孕27周分娩。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Untreated microangiopathic hemolytic anemia in pregnancy is associated with adverse maternal and perinatal outcomes. Accurate diagnosis is challenging owing to nonspecific clinical features and pathologic findings. Timely initiation of appropriate management is essential to optimize maternal and perinatal outcomes. CASE: A 26-year-old primiparous woman presented at 20 weeks of gestation with new-onset microangiopathic hemolytic anemia on a background of poorly controlled type 1 diabetes. She received eculizumab for presumed atypical hemolytic uremic syndrome. At 24 weeks of gestation, she developed superimposed early-onset preeclampsia; she delivered at 27 weeks of gestation after continuing eculizumab. CONCLUSION: Eculizumab may prolong pregnancy in early-onset preeclampsia. Additional research is needed to assess short-term and long-term maternal and newborn outcomes.
引用
- Lu AB, Lazarus B, Rolnik DL, et al. Pregnancy Prolongation After Eculizumab Use in Early-Onset Preeclampsia. Obstet Gynecol. 2019. PMID: 31764731. doi:10.1097/AOG.0000000000003570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。